FWBI Stock Price, First Wave BioPharma, . Quote, Chart

Market Summary

USD2.78+0.14

Market Closed

5.30%

FWBI Stock Price

View Fullscreen

FWBI RSI Chart

FWBI Valuation

Market Cap

5.6M

Price/Earnings (Trailing)

-0.36

EV/EBITDA

-0.09

Price/Free Cashflow

-0.45

MarketCap/EBT

-0.19

FWBI Price/Earnings (Trailing)

FWBI Profitability

Return on Equity

-438.39%

Return on Assets

-229.47%

Free Cashflow Yield

-219.85%

FWBI Fundamentals

FWBI Earnings

Earnings (TTM)

-15.8M

Earnings Growth (Yr)

-2.88%

Earnings Growth (Qtr)

-19.42%

Breaking Down FWBI Revenue

Last 7 days

-2.1%

Last 30 days

-26.5%

Last 90 days

-48.3%

Trailing 12 Months

-2.5%

How does FWBI drawdown profile look like?

FWBI Financial Health

Current Ratio

1.58

FWBI Investor Care

Shares Dilution (1Y)

2513.87%

Diluted EPS (TTM)

-57.88

Tracking the Latest Insider Buys and Sells of First Wave BioPharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	romano sarah	sold	-317	4.2294	-75.00	chief financial officer
Apr 01, 2024	sapirstein james	sold	-735	4.2294	-174	chairman and ceo
Mar 15, 2024	romano sarah	sold	-5,555	4.96	-1,120	chief financial officer
Mar 15, 2024	sapirstein james	sold	-9,359	4.96	-1,887	chairman and ceo
Mar 13, 2024	syage jack	acquired	-	-	15,400	president & coo
Mar 13, 2024	khosla chaitan phd	acquired	-	-	440	-
Jan 12, 2024	romano sarah	sold	-411	4.2	-98.00	chief financial officer
Jan 12, 2024	sapirstein james	sold	-697	4.2	-166	chairman, president and ceo
Jan 02, 2024	coelho mary theresa	acquired	-	-	19,633	-
Jan 02, 2024	riddell alastair	acquired	-	-	19,633	-

Which funds bought or sold FWBI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 17, 2024	Kathleen S. Wright Associates Inc.	unchanged	-	-	4.00	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-4,779	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-15,000	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-3,421	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-23,739	-	-%
Feb 13, 2024	BlackRock Inc.	sold off	-100	-109	-	-%
Feb 13, 2024	FIRST MANHATTAN CO. LLC.	sold off	-100	-	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-3,239	-	-%

Are Funds Buying or Selling FWBI?

Are funds buying FWBI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FWBI

No. of Funds

Unveiling First Wave BioPharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	78,061	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	740,405	SC 13G

Recent SEC filings of First Wave BioPharma, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K/A	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 22, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 18, 2024	DEFA14A	DEFA14A
Mar 18, 2024	8-K	Current Report
Mar 15, 2024	3	Insider Trading

First Wave BioPharma, Inc. News

Latest updates

First Wave BioPharma, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	16.1%	6,883	5,927	4,328	5,534	5,440	4,645	3,927	8,825	11,790	12,424	13,777	17,983	12,924	16,722	6,862	8,184	8,903	9,436	9,612	8,957	7,469
Current Assets	24.6%	4,956	3,977	2,354	3,530	3,413	2,549	1,789	6,550	9,425	7,502	8,615	13,170	7,870	11,538	1,601	2,897	3,408	3,730	3,629	2,804	4,800
Cash Equivalents	12.5%	3,712	3,300	1,200	2,064	1,363	1,700	1,155	5,695	8,249	7,200	8,074	12,026	6,062	11,369	985	1,630	176	1,550	1,311	414	1,114
Net PPE	-33.4%	15.00	22.00	29.00	37.00	44.00	51.00	58.00	66.00	73.00	80.00	89.00	92*	18.00	54.00	62.00	74.00	77.00	95.00	108	125	129
Goodwill	0%	1,684	1,684	1,684	1,684	1,684	1,715	1,756	1,862	1,912	1,945	1,991	1,974	2,054	1,969	1,890	1,844	1,887	1,833	1,914	1,887	1,925
Liabilities	23.9%	3,280	2,648	3,446	2,821	2,698	6,925	18,117	18,065	19,612	19,394	6,740	3,581	15,565	2,657	7,659	5,143	4,286	6,234	6,664	6,243	2,996
Current Liabilities	26.2%	3,133	2,482	3,261	2,625	2,483	6,694	17,284	14,216	12,300	19,098	6,454	3,575	15,545	2,625	7,616	5,143	4,286	5,819	6,221	5,757	2,996
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,285	2,986	1,077	1,947	1,837	1,728	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,077	-	-	-	-
Shareholder's Equity	9.9%	3,603	3,279	882	2,713	2,742	-	-	-	-7,821	6,970	7,037	14,402	-	14,065	-	3,041	4,617	3,202	2,948	2,713	4,474
Retained Earnings	-2.3%	-184,328	-180,200	-176,800	-172,600	-168,533	-164,547	-168,939	-163,500	-153,904	-142,731	-112,330	-103,051	-95,366	-77,965	-72,651	-67,956	-62,694	-61,413	-57,220	-52,177	-47,517
Additional Paid-In Capital	2.4%	187,931	183,505	177,675	175,317	171,276	163,722	156,166	155,571	147,307	137,028	120,585	118,693	93,838	93,240	73,124	72,103	68,576	65,969	61,386	56,135	53,139
Shares Outstanding	131.9%	1,561	673	210	77.00	50.00	11.00	4.00	4.00	4.00	2.00	2.00	1.00	741.67*	-	-	-	-	-	-	-	-
Float	-	-	-	6,700	-	-	-	4,500	-	-	-	67,100	-	-	-	25,200	-	-	-	31,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-3.2%	-3,439	-3,331	-2,761	-2,845	-5,592	-4,254	-4,585	-7,912	-5,862	-15,729	-5,622	-5,073	-5,889	-2,696	-1,343	-1,291	-3,225	-4,153	-4,025	-2,627	-3,340
Share Based Compensation	-52.1%	126	263	293	358	84.00	92.00	375	218	102	182	314	772	153	128	177	55.00	33.00	30.00	-	511	1,135
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-10,248	2.00	-73.93	-	90.00	-	2.00	-4.34	-6.85	-3.91	15*	-13.35	-257
Cashflow From Financing	-19.1%	4,359	5,387	1,933	3,547	5,524	4,772	76.00	5,367	17,073	14,858	1,782	11,051	552	13,060	677	2,756	1,846	4,403	4,928	1,967	255

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FWBI Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development expenses	$ 5,033,218	$ 8,776,302
Research and development recovery - intellectual property acquired		(8,085,045)
General and administrative expenses	10,737,609	11,986,809
Total operating expenses	15,770,827	12,678,066
Loss from operations	(15,770,827)	(12,678,066)
Other expense:
Interest expense	(22,463)	(15,879)
Interest income	2,531	8,415
Loss on dissolution of foreign entity		(1,711,371)
Other expense	(4,224)	(232,741)
Total other expenses	(24,156)	(1,951,576)
Net loss	(15,794,983)	(14,629,642)
Other comprehensive loss:
Dissolution of foreign entity		1,711,371
Foreign currency translation adjustment		(487,236)
Total comprehensive loss	(15,794,983)	(13,405,507)
Net loss	(15,794,983)	(14,629,642)
Deemed dividend on warrant modifications		(47,300)
Preferred stock dividends	(308,128)	(296,127)
Net loss applicable to common shareholders	$ (16,103,111)	$ (14,973,069)
Basic weighted average shares outstanding	336,342	35,912
Diluted weighted average shares outstanding	336,342	35,912
Loss per share applicable to common shareholders - basic	$ (47.88)	$ (416.94)
Loss per share applicable to common shareholders - diluted	$ (47.88)	$ (416.94)

FWBI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 3,711,770	$ 1,362,910
Other receivables		93,014
Prepaid expenses	1,244,466	1,956,831
Total Current Assets	4,956,236	3,412,755
Property, equipment, and leasehold improvements, net	14,565	43,839
Other Assets:
Restricted cash	21,522	21,513
Goodwill	1,684,182	1,684,182
Operating lease right-of-use assets	195,440	259,261
Deposits	11,250	18,149
Total Other Assets	1,912,394	1,983,105
Total Assets	6,883,195	5,439,699
Current Liabilities:
Accounts payable	554,277	720,040
Accrued expenses	825,290	320,176
Accrued dividend payable	1,069,616	761,488
Note payable	612,784	603,494
Operating lease liabilities - current	67,111	66,151
Other current liabilities	4,239	12,138
Total Current Liabilities	3,133,317	2,483,487
Operating lease liabilities - non-current	146,949	214,060
Total Liabilities	3,280,266	2,697,547
Stockholders' Equity:
Common stock - Par value $0.0001 per share; 100,000,000 shares authorized; 1,560,998 and 49,750 shares issued and outstanding at December 31, 2023 and 2022, respectively.	156	5
Additional paid-in capital	187,931,445	171,275,836
Accumulated deficit	(184,328,672)	(168,533,689)
Total Stockholders' Equity	3,602,929	2,742,152
Total Liabilities and Stockholders' Equity	6,883,195	5,439,699
Series B Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series C Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series D Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series E Preferred Stock
Stockholders' Equity:
Preferred stock	$ 0	$ 0

About First Wave BioPharma, Inc.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

CEO	Mr. James R. Sapirstein M.B.A., R.Ph.
WEBSITE	firstwavebio.com
INDUSTRY	Biotechnology
EMPLOYEES	10

First Wave BioPharma, Inc. Frequently Asked Questions

What is the ticker symbol for First Wave BioPharma, Inc.? What does FWBI stand for in stocks?

FWBI is the stock ticker symbol of First Wave BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of First Wave BioPharma, Inc. (FWBI)?

As of Wed May 08 2024, market cap of First Wave BioPharma, Inc. is 5.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FWBI stock?

You can check FWBI's fair value in chart for subscribers.

What is the fair value of FWBI stock?

You can check FWBI's fair value in chart for subscribers. The fair value of First Wave BioPharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of First Wave BioPharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FWBI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is First Wave BioPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether FWBI is over valued or under valued. Whether First Wave BioPharma, Inc. is cheap or expensive depends on the assumptions which impact First Wave BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FWBI.